Evidence map›Paper›PMID 34135504›Full record

ReviewNature reviews. Endocrinology2021

The role of regulated necrosis in endocrine diseases.

Wulf Tonnus, Alexia Belavgeni, Felix Beuschlein, Graeme Eisenhofer, Martin Fassnacht, Matthias Kroiss, Nils P Krone, Martin Reincke, Stefan R Bornstein, Andreas Linkermann

Open access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Structural and molecular principles of DAMP biology.Nature structural & molecular biology · 2026
    Review
  3. Review
  4. Article
  5. What does not kill you makes you Weaker!Cell death and differentiation · 2026
    Article
  6. Article
  7. A STING for necroptosis.Cell death and differentiation · 2026
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Hydrogen Sulfide (HPathogens (Basel, Switzerland) · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Wulf Tonnus *Clinic of Internal Medicine III, Division of Nephrology, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0002-9728-1413
Alexia Belavgeni *Clinic of Internal Medicine III, Division of Nephrology, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.ORCID http://orcid.org/0000-0001-6311-5858
Felix BeuschleinMedizinische Klinik und Poliklinik IV, Hospital of the Ludwig-Maximilian-University Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-7826-3984
Graeme EisenhoferClinic of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.
Martin FassnachtClinic of Internal Medicine I, Division of Endocrinology and Diabetology, University Hospital, University of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0001-6170-6398
Matthias KroissClinic of Internal Medicine I, Division of Endocrinology and Diabetology, University Hospital, University of Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0002-7628-3161
Nils P KroneClinic of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.
Martin ReinckeMedizinische Klinik und Poliklinik IV, Hospital of the Ludwig-Maximilian-University Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-9817-9875
Stefan R BornsteinKlinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland.
Andreas LinkermannClinic of Internal Medicine III, Division of Nephrology, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany. andreas.linkermann@ukdd.de.ORCID http://orcid.org/0000-0001-6287-9725
University Hospital Carl Gustav Carus · DEUniversity of Würzburg · DEKing's College London · GBLudwig-Maximilians-Universität München · DEUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The death of endocrine cells is involved in type 1 diabetes mellitus, autoimmunity, adrenopause and hypogonadotropism. Insights from research on basic cell death have revealed that most pathophysiologically important cell death is necrotic in nature, whereas regular metabolism is maintained by apoptosis programmes. Necrosis is defined as cell death by plasma membrane rupture, which allows the release of damage-associated molecular patterns that trigger an immune response referred to as necroinflammation. Regulated necrosis comes in different forms, such as necroptosis, pyroptosis and ferroptosis. In this Perspective, with a focus on the endocrine environment, we introduce these cell death pathways and discuss the specific consequences of regulated necrosis. Given that clinical trials of necrostatins for the treatment of autoimmune conditions have already been initiated, we highlight the therapeutic potential of such novel therapeutic approaches that, in our opinion, should be tested in endocrine disorders in the future.

Indexed as

AnimalsApoptosisCell DeathEndocrine System DiseasesHumansNecrosisSignal TransductionTherapies, Investigational

Identifiers

PMID34135504
PMCPMC8207819
OpenAlexW3170077424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.